A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

  • Gurney, Howard (Primary Chief Investigator)
  • Butala, Radhika (Research Coordinator)
  • Cunningham, Jacob (Research Coordinator)

Project: Other

Project Details

Short titleD933SC00001
AcronymMISC_AstraZeneca Pty Ltd
Effective start/end date5/10/186/09/23